Clinical Pharmacokinetics
Cure8 research brief
Why This Matters
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve healing and long-term outcomes.
Who Should Pay Attention
Pediatric gastroenterologists, clinicians starting children on infliximab or adalimumab, researchers in IBD pharmacometrics and biomarkers, parents/caregivers of pediatric CD patients, and patients on biologics interested in monitoring drug exposure.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
The study analyzed children starting infliximab or adalimumab with serial blood and stool sampling and objective assessments at one year. For infliximab the authors report specific cTrough targets during induction (for example ~15–26 µg/mL at Week 6, varying by outcome) and higher induction AUC was associated with deep remission.
Rapid infliximab clearance (linked to older age, low albumin, higher BMI, CRP, soluble CD64, and worse disease activity) was associated with lower odds of deep remission. These findings are presented as actionable pharmacokinetic and biomarker thresholds that the authors suggest could guide individualized induction dosing and maintenance strategies.
The paper notes the need for external validation before routine clinical adoption.
Keep In Mind
Findings come from a prospective multicenter cohort (ENvISION) with full PK/PD sampling and objective endoscopic/imaging outcomes, but the authors note the need for external validation before applying the numeric cut-points broadly. Assay methods and local laboratory standards can affect trough/AUC values.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical Pharmacokinetics
PublisherSpringer Science and Business Media LLC
AuthorsAlexander Nasr, Tomoyuki Mizuno, Kei Irie +12 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 26, 2026, 12:00 AM
Content availableMetadata only
Funding disclosed by the source: Leona M. and Harry B. Helmsley Charitable Trust; Division of Diabetes, Endocrinology, and Metabolic Diseases, award R01DK132408; Division of Diabetes, Endocrinology, and Metabolic Diseases, award T32DK007727; Division of Diabetes, Endocrinology, and Metabolic Diseases, award T35DK060444; Division of Diabetes, Endocrinology, and Metabolic Diseases, award P30DK078392
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.